The Efficacy of Topical Formulation Containing Ciplukan (Physalis Angulata Linn.) on Psoriasis Vulgaris Lesions
Launched by UNIVERSITAS PADJADJARAN · Mar 13, 2025
Trial Information
Current as of April 30, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Ciplukan (Physalis angulata Linn.) contains seco-steroids and flavonoids, which exhibit anti-inflammatory, antiproliferative, and immunosuppressive effects. These effects suggest that ciplukan (Physalis angulata Linn.) could serve as an adjuvant topical therapy for psoriasis vulgaris. However, studies on the effectiveness of ciplukan (Physalis angulata Linn.) extract in topical formulations for patients with psoriasis vulgaris have not yet been conducted.
Therefore, a study is needed to assess psoriasis vulgaris lesions both subjectively using the modified PASI score and objectively using ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 18 - 60 years
- • Diagnosed with psoriasis vulgaris based on medical history, physical examination, and severity assessment using the PASI score
- Exclusion Criteria:
- • Pregnant or breastfeeding women.
- • Patients currently undergoing systemic therapy for psoriasis vulgaris.
- • Patients who have not discontinued systemic therapy/phototherapy for psoriasis vulgaris ≤ 30 days.
- • Patients with psoriasis vulgaris who have not discontinued topical therapy (other than moisturizers) ≤ 14 days.
- • Psoriasis vulgaris lesions located in trauma-prone areas, palms, soles, face, and skin folds.
About Universitas Padjadjaran
Universitas Padjadjaran, a prestigious academic institution in Indonesia, is dedicated to advancing medical research and clinical trials that contribute to the improvement of healthcare outcomes. With a strong emphasis on interdisciplinary collaboration and innovation, the university harnesses its extensive resources and expertise to conduct rigorous studies aimed at addressing pressing health challenges. Through its commitment to ethical research practices and community engagement, Universitas Padjadjaran plays a pivotal role in fostering evidence-based medicine and enhancing the quality of life for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bandung, Jawa Barat, Indonesia
Patients applied
Trial Officials
Prof. Dr. Oki Suwarsa, dr., Sp.D.V.E., Subsp.D.A.I., M.Kes
Principal Investigator
Faculty of Medicine Universitas Padjadjaran Bandung
Miranti Pangastuti, dr., Sp.D.V.E., Subsp.D.A.I
Principal Investigator
Faculty of Medicine Universitas Padjadjaran Bandung
Dr. Harry Galuh Nugraha, dr., Sp.Rad(K)
Principal Investigator
Faculty of Medicine Universitas Padjadjaran Bandung
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported